Australia markets open in 9 hours 41 minutes

Boston Scientific Corporation (BSX)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
54.93-0.76 (-1.36%)
At close: 04:00PM EST
55.62 +0.69 (+1.26%)
Pre-market: 08:12AM EST

Boston Scientific Corporation

300 Boston Scientific Way
Marlborough, MA 01752-1234
United States
508 683 4000

IndustryMedical Devices
Full-time employees45,000

Key executives

NameTitlePayExercisedYear born
Mr. Michael F. MahoneyChairman, President & CEO3.77M15.78M1965
Mr. Daniel J. BrennanExecutive VP & CFO1.69M1.96M1966
Mr. Joseph M. FitzgeraldExecutive VP & Group President of Cardiology1.53M3.2M1964
Mr. Jeffrey B. MirvissExecutive VP & President of Peripheral Interventions1.15M977.61k1966
Mr. Arthur Crosswell ButcherExecutive VP and Group President of MedSurg & Asia Pacific1.4M155.24k1971
Mr. John Bradley SorensonExecutive Vice President of Global OperationsN/AN/A1968
Mr. Jonathan R MonsonSenior VP, Global Controller & Chief Accounting OfficerN/AN/AN/A
Ms. Jodi Euerle EddySenior VP and Chief Information & Digital OfficerN/AN/A1973
Ms. Susan Vissers LisaVice President of Investor RelationsN/AN/A1969
Mr. Vance R. BrownSenior VP, General Counsel & Corporate SecretaryN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Corporate governance

Boston Scientific Corporation’s ISS governance QualityScore as of 28 November 2023 is 8. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.